Tranexamic acid

May be taken with or without food.

Hypersensitivity. Active thromboembolic disease (e.g. pulmonary embolism, DVT, cerebral thrombosis), history or risk of thromboembolism (including retinal vein or artery occlusion); fibrinolytic conditions after consumption coagulopathy (unless predominant activation of the fibrinolytic system with acute severe bleeding), history of convulsions; acquired disturbances of colour vision. Severe renal impairment. Concomitant use with combined hormonal contraceptives.

Patient with massive haematuria from the upper urinary tract, uncorrected CV or cerebrovascular disease, subarachnoid haemorrhage. Women with irregular menstrual cycle; not for use prior to menarche or post-menopause. Not recommended for use in patients with acute promyelocytic leukaemia taking oral tretinoin. Mild to moderate renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Perform eye examinations (e.g. visual acuity, intraocular pressure, visual fields, slit lamp) and monitor LFTs regularly during continuous long-term treatment. Monitor for signs and symptoms of hypersensitivity reactions, convulsions, thrombotic events, and ureteral obstruction. For menorrhagia: Exclude structural or histological causes or fibroids distorting the uterine cavity before initiating treatment.

Significant: Visual defects (e.g. changes in colour vision, visual loss), retinal venous and arterial occlusions, ligneous conjunctivitis; convulsions (particularly with high doses of IV inj), severe hypersensitivity reactions (e.g. anaphylaxis or anaphylactoid reaction), venous and arterial thrombosis or thromboembolism; cerebral oedema and infarction (particularly in women with subarachnoid haemorrhage), dizziness. Blood and lymphatic system disorders: Anaemia. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain. General disorders and administration site conditions: Fatigue. Musculoskeletal and connective tissue disorders: Musculoskeletal pain, back pain, muscle cramps or spasm, arthralgia. Nervous system disorders: Headache, migraine. Respiratory, thoracic and mediastinal disorders: Nasal and sinus symptoms. Skin and subcutaneous tissue disorders: Allergic dermatitis.

May exacerbate the procoagulant effects of oral tretinoin in patients with acute promyelocytic leukaemia. Increased risk of thrombosis with factor IX complex concentrates or anti-inhibitor coagulant concentrates; avoid concomitant use. Concomitant use of tranexamic acid with tissue plasminogen activators may reduce the efficacy of both drugs.

Haemostatics

B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.